A roadmap for individualized malignant prostate cancer care

De novo metastatic prostate cancer is a highly lethal form of cancer that affects men. It is characterized by the sudden onset and severity of aggressive cancer lesions in various parts of the body. Approximately 5 to 10 percent of prostate cancer patients are diagnosed with this condition initially. Dr. Alexander Wyatt, a researcher at Vancouver Prostate Centre, has conducted a groundbreaking study that suggests the complexity of cancer within the prostate may play a significant role in tumor growth in this patient population. This finding, published in the journal Nature Cancer, opens up new possibilities for the development of precise treatments for de novo metastatic prostate cancer and other aggressive cancers. Click here to read more.